Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ANEB NYSE:ANVS NASDAQ:ELEV NASDAQ:ONCY On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeANEBAnebulo Pharmaceuticals$0.46-11.5%$0.62$0.30▼$3.42$18.76M-1.9352,944 shs547 shsANVSAnnovis Bio$2.07-2.6%$2.18$1.54▼$5.50$71.37M1.26979,133 shs854,578 shsELEVElevation Oncology$0.37$0.37$0.27▼$0.40$21.62M1.481.34 million shsN/AONCYOncolytics Biotech$0.85-2.6%$0.97$0.33▼$1.51$98.71M1.021.25 million shs846,252 shsTen Starter Stocks For Beginners to Buy NowJust getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceANEBAnebulo Pharmaceuticals0.00%-6.64%+2.22%-3.97%-53.06%ANVSAnnovis Bio0.00%-9.71%+16.85%-12.67%+21.64%ELEVElevation Oncology0.00%0.00%0.00%0.00%+6.85%ONCYOncolytics Biotech0.00%-4.48%-19.81%-19.81%+64.09%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeANEBAnebulo Pharmaceuticals$0.46-11.5%$0.62$0.30▼$3.42$18.76M-1.9352,944 shs547 shsANVSAnnovis Bio$2.07-2.6%$2.18$1.54▼$5.50$71.37M1.26979,133 shs854,578 shsELEVElevation Oncology$0.37$0.37$0.27▼$0.40$21.62M1.481.34 million shsN/AONCYOncolytics Biotech$0.85-2.6%$0.97$0.33▼$1.51$98.71M1.021.25 million shs846,252 shsTen Starter Stocks For Beginners to Buy NowJust getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceANEBAnebulo Pharmaceuticals0.00%-6.64%+2.22%-3.97%-53.06%ANVSAnnovis Bio0.00%-9.71%+16.85%-12.67%+21.64%ELEVElevation Oncology0.00%0.00%0.00%0.00%+6.85%ONCYOncolytics Biotech0.00%-4.48%-19.81%-19.81%+64.09%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceANEBAnebulo Pharmaceuticals 1.50ReduceN/AN/AANVSAnnovis Bio 2.25Hold$13.50550.92% UpsideELEVElevation Oncology 2.00HoldN/AN/AONCYOncolytics Biotech 2.75Moderate Buy$8.50900.00% UpsideCurrent Analyst Ratings BreakdownLatest ANVS, ELEV, ONCY, and ANEB Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/8/2026ONCYOncolytics Biotech Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeSell (E+) ➝ Sell (D-)4/29/2026ANVSAnnovis Bio Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeSell (D-) ➝ Sell (E+)4/24/2026ONCYOncolytics Biotech Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeSell (D-) ➝ Sell (E+)4/14/2026ANVSAnnovis Bio Canaccord Genuity GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$17.003/27/2026ONCYOncolytics Biotech Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)(Data available from 5/17/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookANEBAnebulo PharmaceuticalsN/AN/AN/AN/A$0.28 per shareN/AANVSAnnovis BioN/AN/AN/AN/A$0.64 per shareN/AELEVElevation OncologyN/AN/AN/AN/A$1.02 per shareN/AONCYOncolytics BiotechN/AN/AN/AN/A($0.04) per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateANEBAnebulo Pharmaceuticals-$8.48M-$0.19N/AN/AN/AN/A-74.57%-68.96%5/18/2026 (Estimated)ANVSAnnovis Bio-$28.85M-$1.40N/AN/AN/AN/A-159.43%-133.49%5/19/2026 (Estimated)ELEVElevation Oncology-$44.49M-$0.82N/AN/AN/AN/A-74.68%-48.14%N/AONCYOncolytics Biotech-$28.76M-$0.31N/AN/AN/AN/A-14,442.84%-300.87%7/31/2026 (Estimated)Latest ANVS, ELEV, ONCY, and ANEB EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/18/2026Q3 2026ANEBAnebulo Pharmaceuticals-$0.14N/AN/AN/AN/AN/A5/15/2026Q1 2026ANVSAnnovis Bio-$0.3950-$0.63-$0.2350-$0.63N/AN/A5/14/2026Q1 2026ONCYOncolytics Biotech-$0.05-$0.08-$0.03-$0.08N/AN/A3/31/2026Q4 2025ONCYOncolytics Biotech-$0.06-$0.08-$0.02-$0.08N/AN/A3/13/2026Q4 2025ANVSAnnovis Bio-$0.3084-$0.39-$0.0816-$0.39N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthANEBAnebulo PharmaceuticalsN/AN/AN/AN/AN/AANVSAnnovis BioN/AN/AN/AN/AN/AELEVElevation OncologyN/AN/AN/AN/AN/AONCYOncolytics BiotechN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioANEBAnebulo PharmaceuticalsN/A6.246.24ANVSAnnovis BioN/A5.805.80ELEVElevation Oncology0.6719.4019.40ONCYOncolytics BiotechN/A1.121.12Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipANEBAnebulo Pharmaceuticals28.40%ANVSAnnovis Bio15.83%ELEVElevation Oncology83.70%ONCYOncolytics Biotech6.82%Insider OwnershipCompanyInsider OwnershipANEBAnebulo Pharmaceuticals80.60%ANVSAnnovis Bio20.80%ELEVElevation Oncology8.10%ONCYOncolytics Biotech0.10%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableANEBAnebulo Pharmaceuticals440.79 million7.91 millionNot OptionableANVSAnnovis Bio334.65 million27.44 millionOptionableELEVElevation Oncology4059.22 million54.43 millionOptionableONCYOncolytics Biotech30116.13 million116.01 millionNot OptionableANVS, ELEV, ONCY, and ANEB HeadlinesRecent News About These CompaniesOncolytics Biotech (NASDAQ:ONCY) Stock Rating Lowered by Wall Street ZenMay 16 at 2:07 AM | americanbankingnews.comOncolytics Biotech (ONCY) to Release Quarterly Earnings on WednesdayMay 11, 2026 | americanbankingnews.comOncolytics Biotech (ONCY) Projected to Post Quarterly Earnings on WednesdayMay 6, 2026 | marketbeat.comOncolytics Biotech® Reports Durable Responses in Second-Line RAS-Mutant MSS Colorectal CancerMay 4, 2026 | globenewswire.comOncolytics Biotech Inc. (NASDAQ:ONCY) Given Average Rating of "Moderate Buy" by AnalystsMay 1, 2026 | marketbeat.comOncolytics Biotech, Inc.: Oncolytics Aligns with FDA on Planned Pivotal Anal Cancer StudyApril 27, 2026 | finanznachrichten.deOncolytics Aligns with FDA on Planned Pivotal Anal Cancer StudyApril 27, 2026 | globenewswire.comOncolytics Could Re-Rate As Pelareorep Focuses On Registrational PathsApril 25, 2026 | seekingalpha.comAnalysts Have Conflicting Sentiments on These Healthcare Companies: ArriVent BioPharma, Inc. (AVBP) and Oncolytics Biotech (ONCY)April 12, 2026 | theglobeandmail.comOncolytics Plans FDA Meeting for Pelareorep SCAC StudyApril 7, 2026 | theglobeandmail.comONCY: Initiating Coverage of Oncolytics Biotech; A Focused Path to Unlocking the Potential of PelareorepApril 7, 2026 | msn.comOncolytics Biotech Establishes $75 Million ATM OfferingApril 6, 2026 | tipranks.comOncolytics Biotech® Announces Type C FDA Meeting to Discuss Single-arm Registrational Pathway for Pelareorep in Anal CancerApril 6, 2026 | globenewswire.comOncolytics Biotech’s Nevada Move Resets Capital Access And Dilution Trade OffApril 1, 2026 | finance.yahoo.comOncolytics Biotech® Completes Domicile Change to the United StatesApril 1, 2026 | globenewswire.comThe Patent Cliff is Coming, Driving Smart Money Towards Precision OncologyMarch 19, 2026 | financialpost.comFOncolytics Biotech® to Present New Mechanistic and Translational Data Supporting Pelareorep as an Immune-Priming Backbone at AACR 2026March 19, 2026 | globenewswire.comJames Parsons Acquires 10,000 Shares of Oncolytics Biotech (NASDAQ:ONCY) StockMarch 14, 2026 | insidertrades.comCancer Treatment Breakthroughs Stack Up as Clinical Pipelines AdvanceMarch 4, 2026 | baystreet.caOncolytics Biotech® Launches Randomized Colorectal Cancer StudyMarch 2, 2026 | globenewswire.comImmuno-Oncology Investments Accelerate as Pipeline Catalysts Multiply in 2026February 25, 2026 | newswire.caNew MarketBeat Followers Over TimeMedia Sentiment Over Time Top HeadlinesView All Headlines$39 Trillion Debt Signal: 3 TIPS ETFs to Hedge Persistent InflationBy Chris Markoch | April 19, 2026Chevron's Pullback May Be a Buying Opportunity—Even If the War EndsBy Sam Quirke | April 26, 2026Avis Short Squeeze Shocked the Market: Are These 3 Stocks Next?By Dan Schmidt | April 27, 20263 Agriculture Stocks to Buy as Food Inflation Stays Elevated in 2026By Chris Markoch | April 20, 2026Powering Up: UGI Banks $685M in Strategic TurnaroundBy Jeffrey Neal Johnson | May 4, 2026ANVS, ELEV, ONCY, and ANEB Company DescriptionsAnebulo Pharmaceuticals NASDAQ:ANEB$0.46 -0.06 (-11.54%) As of 05/15/2026 03:49 PM EasternAnebulo Pharmaceuticals, Inc., a clinical-stage biotechnology company, engages in developing solutions for people suffering from acute cannabinoid intoxication (ACI) and substance addiction. The company's lead product candidate is ANEB-001, a small molecule cannabinoid receptor antagonist, which is in a Phase II clinical trial to address the unmet medical need for a specific antidote for ACI. Anebulo Pharmaceuticals, Inc. was incorporated in 2020 and is based in Lakeway, Texas.Annovis Bio NYSE:ANVS$2.07 -0.06 (-2.63%) Closing price 05/15/2026 03:59 PM EasternExtended Trading$2.08 +0.00 (+0.05%) As of 05/15/2026 06:10 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Annovis Bio, Inc., a clinical stage drug platform company, develops drugs to treat neurodegeneration. The company's lead product candidate is Buntanetap, which has completed three Phase 1/2 clinical trials for the treatment of Alzheimer's disease (AD), Parkinson's disease, and other chronic neurodegenerative diseases. It is also developing ANVS405, which is in Phase 2 and Phase 3 efficacy studies, an intravenous drug for protecting the brain after traumatic brain injury and/or stroke; and ANVS301, which is in Phase I clinical trials, an orally administered drug to increase cognitive capability in later stages of AD and dementia. The company was incorporated in 2008 and is based in Malvern, Pennsylvania.Elevation Oncology NASDAQ:ELEVElevation Oncology, Inc., an oncology company, focuses on the discovery and development of cancer therapies to treat patients across a range of solid tumors with significant unmet medical needs. The company's lead candidate is EO-3021, an antibody-drug conjugate designed to target Claudin 18.2, a clinically validated molecular target. Its EO-3021 selectively delivers a cytotoxic payload directly to cancer cells expressing Claudin 18.2. Elevation Oncology, Inc. has a license agreement with CSPC Megalith Biopharmaceutical Co., Ltd. to develop and commercialize EO-3021. The company was formerly known as 14ner Oncology, Inc. and changed its name to Elevation Oncology, Inc. in February 2020. The company was incorporated in 2019 and is based in Boston, Massachusetts.Oncolytics Biotech NASDAQ:ONCY$0.85 -0.02 (-2.62%) Closing price 05/15/2026 04:00 PM EasternExtended Trading$0.86 +0.01 (+1.18%) As of 05/15/2026 07:48 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Oncolytics Biotech Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of pharmaceutical products for the treatment of cancer. The company is developing pelareorep, an intravenously delivered immunotherapeutic agent, which is in phase 3 clinical trial for the treatment of hormone receptor-positive / human epidermal growth factor 2-negative metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma. It has a co-development agreement with Merck KGaA and Pfizer Inc. to co-develop pelareorep, as well as with Roche Holding AG. The company was incorporated in 1998 and is headquartered in Calgary, Canada. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Peloton Stock Gives Back Gains After Upbeat Earnings Report MarketBeat Week in Review – 05/11 - 05/15 Datavalut Gains Traction: 5 Reasons to Sell Now TMC Stock: Why This Pre-Revenue Miner Is Worth Watching Alphabet's Googlebook Brings Gemini AI to PC Hardware As Broadcom Eclipses $2 Trillion, Private Credit Giants Wants In Robinhood, SoFi, and Webull Are Telling Very Different Stories Viking Sails to All-Time Highs—Fundamentals Signal More to Come Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
